Hints and tips:
Related Special Reports
...However, Steensberg stressed his company, which joined forces with German pharma group Boehringer Ingelheim more than a decade ago to develop a weight loss drug that is now in late-stage trials, wanted to...
...German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate....
...at Boehringer Ingelheim....
...Carinne Brouillon, Boehringer Ingelheim’s head of human pharma, said she expected to bring the drug to market in 2027 or 2028, making it the third drugmaker to commercialise the new kind of weight-loss drug...
...Impressive results also emerged for German pharma group Boehringer Ingelheim and Zealand Pharma’s survodutide....
...He now hopes to bring a case to trial alleging that the product — sold by GSK, Sanofi, Pfizer and Boehringer Ingelheim over many years, caused his disease....
...Survodutide, which Boehringer Ingelheim developed with Danish biotech Zealand Pharma, copies a hormone called GLP-1 to reduce appetite in the same way as the existing drugs....
...It is trialling Survodutide, developed with Boehringer Ingelheim, along with an earlier-stage drug petrelintide. This mimics the amylin hormone, and may have fewer side-effects....
...German pharma group Boehringer Ingelheim is commercialising a Zealand treatment for both obesity and liver disease that is set to launch by 2028....
...German pharma group Boehringer Ingelheim and Copenhagen-based Zealand Pharma said their weight-loss drug had achieved positive results in liver disease trials....
...Boehringer Ingelheim is building a new manufacturing plant but, says Dias of the EMA, “you don’t build a new site overnight”....
...The initial list of 10 drugs to face price negotiations includes a diabetes pill called Jardiance sold by Boehringer Ingelheim and Eli Lilly; a medicine to prevent strokes called Eliquis made by Pfizer and...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...Before that, it was marketed by the private drugmaker Boehringer Ingelheim from 2006 to 2017, Pfizer from 2000 to 2006, and GSK from 1995 to 1998....
...As the lawsuits move towards trial, companies who sold branded versions of Zantac over the past 35 years — including GSK, Sanofi, Pfizer and Boehringer Ingelheim Pharmaceuticals — have denied that using...
...Ingelheim....
...“We all agree that we need to rethink how this market works,” says Hubertus von Baumbach, head of German pharmaceutical group Boehringer Ingelheim, and chair of the European Federation of Pharmaceutical...
...That would have been close to the multiple of 22 times operating earnings before usual deductions used to price Sanofi’s €21.8bn asset swap with Boehringer Ingelheim last year....
...Boehringer Ingelheim, Europe’s biggest private drugmaker, hired Simone Menne as chief financial officer from airline Lufthansa....
...The move comes less than three years after Lilly bought Novartis’s animal health unit for $5.4bn and 10 months after it acquired an animal vaccines division from Boehringer Ingelheim, which helped the group...
...Engelbert Coster Tjeenk Willink, a former executive at German pharma group Boehringer Ingelheim, will become CEO on an interim basis, the board said....
...Engelbert Coster Tjeenk Willink, a former executive at German pharma group Boehringer Ingelheim, will take the chief executive role on an interim basis, the board said....
...However, two other versions are now available: Canagliflozin, which is manufactured by Janssen, and Empagliflozin, developed jointly by Boehringer Ingelheim and Eli Lilly & Co, putting pressure on AstraZeneca...
...A $2.6bn cash and stock takeover of Roxane (since renamed West-Ward Columbus) the US generic drugs unit of Germany’s Boehringer Ingelheim, was meant to change that. Initially, it did the opposite....
...Even so, the big multinationals — under pressure to focus — have been hiving off their animal medicine arms: Novartis to Eli Lilly; Sanofi of France to Boehringer Ingelheim....
International Edition